These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

729 related items for PubMed ID: 15979320

  • 1. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL, Marcus R, Bradley JA.
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
    [Abstract] [Full Text] [Related]

  • 2. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH, Russ GR, Coates PT.
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [Abstract] [Full Text] [Related]

  • 3. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM, Crawford DH.
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [Abstract] [Full Text] [Related]

  • 4. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 5. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 6. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW.
    J Clin Oncol; 2009 Jul 10; 27(20):3354-62. PubMed ID: 19451438
    [Abstract] [Full Text] [Related]

  • 7. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.
    Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ.
    Transpl Int; 2007 Mar 10; 20(3):207-18. PubMed ID: 17291214
    [Abstract] [Full Text] [Related]

  • 8. Posttransplant lymphoproliferative disorder.
    Everly MJ, Bloom RD, Tsai DE, Trofe J.
    Ann Pharmacother; 2007 Nov 10; 41(11):1850-8. PubMed ID: 17940127
    [Abstract] [Full Text] [Related]

  • 9. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 10; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 10. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient.
    Dharnidharka VR, Douglas VK, Hunger SP, Fennell RS.
    Pediatr Transplant; 2004 Feb 10; 8(1):87-90. PubMed ID: 15009846
    [Abstract] [Full Text] [Related]

  • 11. Post-transplant lymphoproliferative disorder: a review.
    Loren AW, Porter DL, Stadtmauer EA, Tsai DE.
    Bone Marrow Transplant; 2003 Feb 10; 31(3):145-55. PubMed ID: 12621474
    [Abstract] [Full Text] [Related]

  • 12. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML, Swinnen LJ, Plaisance KT, Schnell C, Grogan TM, Schneider BG, Southwest Oncology Group.
    Transplantation; 2003 Sep 27; 76(6):959-64. PubMed ID: 14508361
    [Abstract] [Full Text] [Related]

  • 13. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
    Hao QF, Sheng GY, Luan Z.
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep 27; 15(9):795-9. PubMed ID: 24034931
    [Abstract] [Full Text] [Related]

  • 14. Treatment for Epstein-Barr virus-associated PTLD.
    Gross TG.
    Herpes; 2009 Jan 27; 15(3):64-7. PubMed ID: 19306606
    [Abstract] [Full Text] [Related]

  • 15. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis.
    Capello D, Rossi D, Gaidano G.
    Hematol Oncol; 2005 Jun 27; 23(2):61-7. PubMed ID: 16216037
    [Abstract] [Full Text] [Related]

  • 16. Post-transplant lymphoproliferative disorders.
    Singavi AK, Harrington AM, Fenske TS.
    Cancer Treat Res; 2015 Jun 27; 165():305-27. PubMed ID: 25655616
    [Abstract] [Full Text] [Related]

  • 17. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients.
    Preiksaitis JK.
    Clin Infect Dis; 2004 Oct 01; 39(7):1016-23. PubMed ID: 15472855
    [Abstract] [Full Text] [Related]

  • 18. Transplantation-related lymphoproliferative disorder: a model for human immunodeficiency virus-related lymphomas.
    Swinnen LJ.
    Semin Oncol; 2000 Aug 01; 27(4):402-8. PubMed ID: 10950366
    [Abstract] [Full Text] [Related]

  • 19. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, Balistreri WF, Hornung RW.
    Transplantation; 2003 Apr 15; 75(7):987-93. PubMed ID: 12698085
    [Abstract] [Full Text] [Related]

  • 20. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M, Badwal S, Pandey R, Srivastava A, Sharma RK, Gupta RK.
    Clin Transplant; 2005 Oct 15; 19(5):668-73. PubMed ID: 16146560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.